ArticleBMC immunology2020

Patient experience with subcutaneous immunoglobulin 20%, Ig20Gly, for primary immunodeficiency diseases: a prespecified post hoc analysis of combined data from 2 pivotal trials.

Lisa M Meckley et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.